专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10800741B2 Quinoline compound, preparation method and medical use therefor 有权
公开(公告)号：US10800741B2
公开(公告)日：2020-10-13
申请号：US16480292
申请日：2018-02-06
申请人： ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD.
发明人： Jutong Si , Meifeng Jiang , Jiayan Li , Han Zeng , Huabin Yang
IPC分类号： C07D215/16 , A61P35/00 , C07D401/12 , A61K31/47
摘要： The present invention relates to a quinoline compound, as well as a preparation method and medical use therefor. Specifically, the present invention relates to a novel quinolone compound represented by the general formula (I) and a method for preparing the same, as well as a use therefor as an inhibitor for a plurality of protein kinases, and a use in the prevention and/or treatment of cancer in particular; the definition of each group in the general formula (I) is the same as the definition in the description.

2. 发明授权

US08912333B2 Polymorphs of pitavastatin calcium 有权
标题翻译：匹伐他汀钙的多晶型物
公开(公告)号：US08912333B2
公开(公告)日：2014-12-16
申请号：US13884734
申请日：2011-08-23
申请人： Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Samala Malla Reddy , Bandi Vamsi Krishna
发明人： Bandi Parthasaradhi Reddy , Kura Rathnakar Reddy , Dasari Muralidhara Reddy , Samala Malla Reddy , Bandi Vamsi Krishna
IPC分类号： C07D215/04 , C07D215/16
CPC分类号： C07D215/04 , C07D215/14 , C07D215/16
摘要： The present invention provides a solid of pitavastatin tert-butyl ester and process for its preparation. The present invention also provides a novel crystalline form of pitavastatin calcium, process for its preparation and pharmaceutical compositions comprising it.
摘要翻译：本发明提供了匹伐他汀叔丁酯的固体及其制备方法。本发明还提供了匹伐他汀钙的新型结晶形式，其制备方法和包含它的药物组合物。

3. 发明授权

US08802675B2 Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them 有权
标题翻译：神经保护性多功能化合物和包含它们的药物组合物
公开(公告)号：US08802675B2
公开(公告)日：2014-08-12
申请号：US13146975
申请日：2010-01-31
申请人： Moussa B. H. Youdim , Mati Fridkin , Hailin Zheng
发明人： Moussa B. H. Youdim , Mati Fridkin , Hailin Zheng
IPC分类号： A01N43/64 , A61K31/53 , A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , A61K31/497 , A01N43/54 , A61K31/517 , A01N43/42 , A61K31/47 , A01N43/40 , A61K31/445 , A01N47/10 , A61K31/27 , A01N33/02 , A61K31/135 , A61K31/13 , C07D253/08 , C07D487/00 , C07D239/72 , C07D241/36 , C07D401/00 , C07D215/16 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D417/00 , C07D419/00 , C07D421/00 , C07C211/00
CPC分类号： C07C259/10 , C07C211/38 , C07C271/40 , C07C2602/08 , C07C2603/74 , C07D215/34 , C07D401/06 , C07D401/12
摘要： Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and/or treated by iron chelation therapy, and/or neuroprotection and/or neurorestoration, and/or apoptosis inhibition and/or MAO inhibition and/or cholinesterase inhibition and/or NMADR inhibition. The present invention encompasses compounds of the formulas I to VI.
摘要翻译：提供多官能化合物，其包含两个或多个选自以下的官能部分：（i）赋予铁螯合剂功能的部分; （ii）赋予神经保护功能的部分; （iii）赋予组合的抗细胞凋亡，神经保护和/或神经恢复功能的部分; （iv）赋予脑MAO抑制的部分，优选在肝脏和小肠中几乎没有MAO抑制作用; （v）赋予胆碱酯酶抑制功能的部分; 和（vi）赋予N-甲基-D-天冬氨酸受体（NMDAR）抑制的部分及其药学上可接受的盐和旋光异构体。多官能化合物可用于治疗或预防可通过铁螯合治疗和/或神经保护和/或神经恢复，和/或凋亡抑制和/或MAO抑制和/或MAO抑制和/或治疗的/ 或胆碱酯酶抑制和/或NMADR抑制。本发明包括式I至VI的化合物。

4. 发明授权

US07973160B2 Nitrogen-containing aromatic derivatives 有权
标题翻译：含氮芳香族衍生物
公开(公告)号：US07973160B2
公开(公告)日：2011-07-05
申请号：US12244227
申请日：2008-10-02
申请人： Yasuhiro Funahashi , Toru Haneda , Junichi Kamata , Tatsuo Watanabe , Hiroshi Obaishi , Junji Matsui
发明人： Yasuhiro Funahashi , Toru Haneda , Junichi Kamata , Tatsuo Watanabe , Hiroshi Obaishi , Junji Matsui
IPC分类号： C07D487/04 , A61K31/519 , A61K31/47 , C07D215/16 , A61P9/10 , A61P35/04
CPC分类号： C07D213/73 , A61K31/4706 , A61K31/4745 , A61K31/517 , A61K31/519 , C07D207/34 , C07D213/26 , C07D213/68 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D215/18 , C07D215/233 , C07D215/36 , C07D215/38 , C07D215/48 , C07D239/34 , C07D239/42 , C07D239/47 , C07D239/88 , C07D249/04 , C07D261/14 , C07D277/48 , C07D307/68 , C07D319/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04
摘要： Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.
摘要翻译：由以下通式表示的化合物：其中Ag是任选取代的5至14元杂环基等; Xg为-O-，-S-等; Yg是任选取代的C 6-14芳基，任选取代的5至14元杂环基等; Tg1为下列通式表示的基团：（其中Eg为单键或-N（Rg2） - ，Rg1和Rg2各自独立地表示氢原子，可以具有取代基的C1-6烷基等，Zg 表示C 1-8烷基，C 3-8脂环族烃基，C 6-14芳基等）]，其盐或前述的水合物。

5. 发明申请

US20100249182A1 AMINOQUINOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 有权
标题翻译：氨基喹啉衍生物，其制备方法和包含其的药物组合物
公开(公告)号：US20100249182A1
公开(公告)日：2010-09-30
申请号：US12468292
申请日：2009-05-19
申请人： Kyung-Ho YOO , Dong-Jin KIM , Bong-Soo NAM , Chang-Hyun OH , So-Ha LEE , Seung-Joo CHO , Tae-Bo SIM , Jung-Mi HAH
发明人： Kyung-Ho YOO , Dong-Jin KIM , Bong-Soo NAM , Chang-Hyun OH , So-Ha LEE , Seung-Joo CHO , Tae-Bo SIM , Jung-Mi HAH
IPC分类号： A61K31/47 , C07D215/16
CPC分类号： C07D215/233 , A61K31/47 , C07D401/12 , C07D413/12
摘要： Provided are a novel aminoquinoline compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, preparation method thereof, and a pharmaceutical composition for preventing or treating cutaneous cancer, comprising the aminoquinoline compound or pharmaceutically acceptable salt thereof. Since the compound of Formula 1 exhibits excellent anti-proliferative effect on melanoma tumor cells, it is useful for preventing or treating cutaneous cancer. wherein R1, R2, and R3 are defined in the specification.
摘要翻译：提供一种由式1表示的新型氨基喹啉化合物或其药学上可接受的盐，其制备方法和用于预防或治疗皮肤癌的药物组合物，其包含氨基喹啉化合物或其药学上可接受的盐。由于式1的化合物对黑素瘤肿瘤细胞具有优异的抗增殖作用，因此可用于预防或治疗皮肤癌。其中R1，R2和R3在说明书中定义。

6. 发明授权

US07511157B2 Hepatitis C inhibitor dipeptide analogs 有权
标题翻译：丙型肝炎抑制剂二肽类似物
公开(公告)号：US07511157B2
公开(公告)日：2009-03-31
申请号：US11185671
申请日：2005-07-19
申请人： Murray D. Bailey , Punit Bhardwaj , Elise Ghiro , Nathalie Goudreau , Teddy Halmos , Montse Llinas-Brunet , Marc-André Poupart , Jean Rancourt
发明人： Murray D. Bailey , Punit Bhardwaj , Elise Ghiro , Nathalie Goudreau , Teddy Halmos , Montse Llinas-Brunet , Marc-André Poupart , Jean Rancourt
IPC分类号： C07D207/48 , C07D207/08 , C07D215/12 , C07D215/16 , C07D215/06
CPC分类号： C07D413/04 , A61K38/00 , C07K5/06139 , C07K5/06191
摘要： Compounds of formula (I): wherein R1, R2, R3, R4, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.
摘要翻译：式（I）化合物：其中R 1，R 2，R 3，R 4，n和m如本文所定义。该化合物可用作HCV NS3蛋白酶的抑制剂。

7. 发明申请

US20080312273A1 Quinoline Derivatives Having Vegf Inhibiting Activity 审中-公开
标题翻译：喹啉衍生物具有抑制活性
公开(公告)号：US20080312273A1
公开(公告)日：2008-12-18
申请号：US11947533
申请日：2007-11-29
申请人： Laurent Francois Andre Hennequin
发明人： Laurent Francois Andre Hennequin
IPC分类号： A61K31/47 , C07D215/16 , A61P9/00
CPC分类号： C07D401/12 , C07D401/14
摘要： The invention relates to compounds of formula (I) wherein: either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH— or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or direct bond; Z is linked to any one of G1, G2, G3, and G4; n is an integer from 0 to 5; m is an integer from 0 to 3; Ra represents hydrogen or fluoro; Rb, R1 and R2 are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.
摘要翻译：本发明涉及式（I）化合物，其中：G 1，G 2，G 3，G 4和G 5中的任一个为氮，其余四个为-CH-或G 1，G 3，G 3，G 4和G 5均为-CH- ; Z是-O-，-NH-，-S-，-CH 2 - 或直接键; Z连接到G1，G2，G3和G4中的任一个; n为0〜5的整数， m是0至3的整数; Ra表示氢或氟; 本文定义了Rb，R1和R2及其盐，制备方法使得这些化合物，含有式I化合物的药物组合物或其药学上可接受的盐作为活性成分，以及式I化合物在制备用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物。式I化合物及其药学上可接受的盐抑制VEGF的作用，其在治疗许多疾病状态（包括癌症和类风湿性关节炎）中是有价值的。

8. 发明授权

US07375218B2 Process for preparing macrocyclic HCV protease inhibitors 有权
标题翻译：制备大环HCV蛋白酶抑制剂的方法
公开(公告)号：US07375218B2
公开(公告)日：2008-05-20
申请号：US11222950
申请日：2005-09-09
申请人： Fabrice Gallou
发明人： Fabrice Gallou
IPC分类号： C07D215/16 , C07K5/08
CPC分类号： C07K5/06078 , A61K38/00 , C07K5/0804
摘要： Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection:
摘要翻译：公开了用于制备式（I）化合物的高度收敛的方法，该化合物是用于治疗丙型肝炎病毒（HCV）感染的有效活性剂：

9. 发明授权

US07317102B2 Diarylmethyl and related compounds 失效
标题翻译：二芳基甲基和相关化合物
公开(公告)号：US07317102B2
公开(公告)日：2008-01-08
申请号：US10813745
申请日：2004-03-31
申请人： Mathai Mammen , Adam Hughes
发明人： Mathai Mammen , Adam Hughes
IPC分类号： C07D215/12 , C07D215/16
CPC分类号： C07D401/12 , C07D207/04 , C07D207/09 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/06 , C07D409/12 , C07D409/14
摘要： This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, Ar1, Ar2, E, a, b, c and z are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such compounds are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
摘要翻译：本发明提供了式I化合物：其中R 1，R 2，R 3，R 4，R 4， R 5，R 6，R 7，Ar 1，Ar 2，E 2，，a，b，c和z如说明书中所定义，或其药学上可接受的盐或溶剂合物或立体异构体。本发明的化合物具有β2/2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性，因此，这些化合物可用于治疗肺部疾病，如慢性阻塞性肺疾病和哮喘。

10. 发明申请

US20070270461A1 Fungicide 审中-公开
标题翻译：杀菌剂
公开(公告)号：US20070270461A1
公开(公告)日：2007-11-22
申请号：US11436341
申请日：2006-05-18
申请人： Daniel F. Heiman , Peter D. Petracek , Judith A. Fugiel , Prem Warrior
发明人： Daniel F. Heiman , Peter D. Petracek , Judith A. Fugiel , Prem Warrior
IPC分类号： A01N43/42 , C07D215/16
CPC分类号： C07D215/227 , A01N43/42
摘要： 5,7-Dibromo-8-(2-hydroxyethoxy) quinoline, 5,7-dibromo-8-(2-methoxycarbonylethoxy) quinoline, fungicidal compositions containing these compounds and methods of treating plant diseases with these compounds.
摘要翻译： 5,7-二溴-8-（2-羟基乙氧基）喹啉，5,7-二溴-8-（2-甲氧基羰基乙氧基）喹啉，含有这些化合物的杀真菌组合物以及用这些化合物处理植物病害的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式